Platform for discovering cell penetrating peptides based on phage display and methods of making and using same

By inserting exogenous peptidases to recognize amino acid sequences in M13 phage pIII, a new CPP discovery platform was developed, which solved the problem of low efficiency of existing CPP in cell internalization, and achieved efficient cytoplasmic internalization and delivery of therapeutic agents. .

CN119032171APending Publication Date: 2024-11-26ELI LILLY & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034451.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-17
Filing Date
2023-02-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing cell penetrating peptides (CPPs) exhibit poor uptake efficiency when carrying loads, are easily captured and degraded by endosomal vesicles, resulting in low efficiency in cytoplasm internalization, and complex existing findings and penetration measurement methods. And inaccurate.

Method used

Develop a CPP discovery platform based on engineered M13 phages, by inserting exogenous peptidase into the phage pIII coat protein to recognize amino acid sequences, making it lose infectivity under the action of lysosomal peptidases, thus skipping lysosomal localization and directly Enter the cytoplasm and use this platform to screen out efficient CPP.

Benefits of technology

Achieve efficient discovery and screening of CPPs with improved cytoplasmic uptake efficiency and reduced lysosomal localization, providing a novel method to deliver therapeutic agents such as siRNA and nanoparticles, avoiding the endosomal-lysosomal pathway and enhancing the cells Internalization efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032171A_ABST
    Figure CN119032171A_ABST
Patent Text Reader

Abstract

An engineered bacteriophage comprising modification of a pIII surface coat protein, in particular at least one of the GS1 and GS2 linkers, to comprise a peptidase recognition amino acid sequence therein. Also disclosed are methods of finding novel cell penetrating peptides (CPPs) using such engineered bacteriophages. Novel CPPs are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present disclosure relates generally to biology and protein engineering, and more specifically to phage display technology, in particular to engineered M13 phage vectors containing one or more cathepsin-cleaved substrates, particularly in the glycine / serine-rich (GS) 1 linker and / or GS2 linker of protein III (pIII), to serve as a discovery platform for novel cell penetrating peptides (CPPs).

[0002] RNA interference (RNAi) is a process that uses double-stranded RNA (dsRNA) to silence gene expression. RNAi is induced by short (<30 nucleotides) double-stranded RNA ("dsRNA") molecules present in cells (Fire et al., 1998, Nature 391:806-811). These short dsRNA molecules, called "short interfering RNA" or "siRNA", cause the destruction of messenger RNA ("mRNA") with sequence homology to the siRNA (Elbashir et al., 2001, Genes Dev, 15:188-200). It is believed that one strand of the siRNA is integrated into a ribonucleoprotein complex called the RNA-induced silencing complex (RISC). RISC uses this siRNA strand to recognize mRNA molecules that are at least partially complementary to the integrated siRNA strand, and then cuts these target mRNAs or inhibits their translation. siRNAs are apparently recycled like multi-turnover enzymes, with one siRNA molecule being able to induce the cutting of approximately 1000 mRNA molecules. Therefore, siRNA-mediated RNAi degradation of mRNA is more efficient than currently available technologies for inhibiting target gene expression.

[0003] The successful active transport of therapeutic agents and / or carriers of such therapeutic agents to intracellular targets requires cell membrane translocation. Although the cell membrane is selectively permeable to compounds and molecules essential for cell function and survival, it is still a particularly difficult barrier to cross. Since intracellular targets of therapeutic agents are three to four times more numerous than cell surface targets, many delivery systems have been developed to help therapeutic agents such as peptides and siRNAs cross the cell membrane and reach their intracellular targets.

[0004] One such therapeutic delivery system is a cell-penetrating peptide (CPP), which is a versatile delivery vehicle across the cell membrane (see, e.g., Peraro, L and Kritzer, JAE merging methods and design principles for cell-penetrant peptides. Angew. Chem. Int. Ed. Engl., 57, 11868-11881 (2018)), and is commonly used to carry various therapeutic payloads, such as antibodies, siRNAs, and nanoparticles, which cannot penetrate cells into the intracellular region containing about two-thirds of the human proteome (Overington, A1-Lazikani, & Hopkins, 2006). More specifically, CPP is a family of short peptides, typically 5-39 amino acids in length, and are typically cationic, amphipathic, or hydrophobic. Unfortunately, many CPPs exhibit poor uptake efficiency when carrying a payload and are primarily captured by endosomal vesicles, resulting in lysosomal degradation. The difficulty in distinguishing between cytoplasmic uptake and endosomal capture molecules has hindered the identification of true CPPs for therapeutic purposes.

[0005] Known methods for CPP discovery and permeability measurement typically require dyes and labels on the CPP and involve complex mammalian cell engineering for intracellular detection by microscopy or flow cytometry. Current shortcomings of cellular uptake studies include confounding effects of conjugated dyes and labels and frequent endosomal capture with subsequent degradation.

[0006] Although methods for CPP discovery and penetration measurement already exist, additional CPP discovery platforms are needed to screen and discover CPPs with improved uptake efficiency and reduced lysosomal degradation (i.e., true cytoplasmic internalization).

[0007] Therefore, new CPPs are being sought, which have improved cytoplasmic uptake efficiency and reduced lysosomal localization, and therapeutic agents including peptides, polypeptides and oligonucleotides are effectively targeted and delivered to the cytoplasm. To meet this demand, the inventors have designed a CPP discovery platform based on sophisticated engineered phages, which includes an engineered phage library, and a method for effectively identifying new and surprisingly effective CPPs using the phage library. More specifically, the disclosure is based in part on the development of engineered M13 phages, which have modified pIII that are susceptible to lysosomal proteases and / or peptidases (including but not limited to one or more cathepsins). As shown herein, because the N1 and N2 domains are removed after lysosomal peptidase digestion, the modified pIII loses its ability to infect bacteria after exposure to lysosomal peptidases, which can be used to screen for putative CPPs (i.e., CPPs that enter the cytoplasmic region by skipping lysosomal localization) by direct translocation or by avoiding endosomes to reach cytoplasmic localization. It is noteworthy that subsequent mechanism of action studies have shown that CPPs identified using the engineered phage-based CPP discovery platform disclosed herein enter cells through a unique pathway. Therefore, the CPP discovery platform disclosed herein provides a novel and efficient method for high-throughput discovery of cell type selective CPPs with sequences that are very different from traditional cell penetrating peptides.

[0008] Thus, the present disclosure first describes an engineered M13 phage, wherein the engineered phage comprises at least a modified pill, and wherein the modified pill comprises at least one exogenous peptidase recognition amino acid sequence that functions as a universal or cell type-specific peptidase cleavage substrate, which in some embodiments comprises a cathepsin cleavage substrate.

[0009] In some embodiments, the present disclosure provides a modified bacteriophage pill coat protein of the following formula (from amino terminus (N terminus) to carboxyl terminus (C terminus)): display peptide-N1-GS1-N2-GS2-CT, wherein the C terminus of the peptide is fused to the N terminus of N1, and wherein a total of 1 to 4 exogenous peptidase recognition amino acid sequences are present in GS1 and GS2 of the pill coat protein.

[0010] In some cases, the peptidase recognition amino acid sequence is inserted into at least one of the GS1 joint and the GS2 joint of pill. In other cases, the peptidase recognition amino acid sequence is inserted into the GS1 joint or the GS2 joint, especially the GS2 joint. In some cases, the peptidase recognition amino acid sequence is inserted into both the GS1 joint and the GS2 joint. In some cases, the peptidase recognition amino acid sequence is inserted in a single copy. In other cases, the peptidase recognition amino acid sequence can be inserted in multiple copies, for example, one copy, two copies or three copies of the peptidase recognition amino acid sequence. In some cases, when multiple copies of the peptidase recognition amino acid sequence are inserted into the GS1 joint and / or the GS2 joint, these peptidase recognition amino acid sequences can be the same. In other cases, when multiple copies of the peptidase recognition amino acid sequence are inserted into the GS1 joint and / or the GS2 joint, these peptidase recognition amino acid sequences can be different. In some cases, the peptidase recognition amino acid sequence is Phe-Leu-Val-Ile-Arg (i.e., FLVIR) (SEQ ID NO: 4).

[0011] In some cases, the phage is a wild-type M13 having a nucleotide sequence of SEQ ID NO: 1, which is modified to include a nucleotide sequence encoding at least one exogenous peptidase recognition amino acid sequence in pill. In other cases, the phage is an M13IX1 04 having a nucleotide sequence of SEQ ID NO: 2, which is modified to include a nucleotide sequence encoding at least one exogenous peptidase recognition amino acid sequence in pill. In other cases, the phage is an engineered M13IX1 04 having a nucleotide sequence of SEQ ID NO: 3. In some cases, at least one exogenous peptidase recognition amino acid sequence is inserted into the GS1 linker of pill. In other cases, at least one exogenous peptidase recognition amino acid sequence is inserted into the GS2 linker of pill. In still other cases, at least one exogenous peptidase recognition amino acid sequence is inserted into both the GS1 linker and the GS2 linker.

[0012] In some cases, the GS1 linker originally had the nucleotide sequence of SEQ ID NO: 7 or 8. In some cases, the GS2 linker originally had the nucleotide sequence of SEQ ID NO: 9 or 10.

[0013] In some cases, the engineered pIII further comprises a CPP connected thereto. In some cases, the CPP is a known CPP. In other cases, the CPP is a putative CPP. In some cases, the putative or known CPP is a peptide of 4 to 39 amino acid residues. In other cases, it is a peptide of about 8 or 9 amino acids.

[0014] In some cases, the engineered phage comprises the nucleotide sequence of SEQ ID NO:3.

[0015] Second, the disclosure describes engineered pills comprising at least one exogenous peptidase recognition amino acid sequence that functions as a universal or cell type specific cathepsin cleavage substrate.

[0016] In some cases, the peptidase recognition amino acid sequence is inserted into at least one of the GS1 joint and the GS2 joint of pill. In other cases, the peptidase recognition amino acid sequence is inserted into the GS1 joint or the GS2 joint, especially the GS2 joint. In some cases, the peptidase recognition amino acid sequence is inserted into both the GS1 joint and the GS2 joint. In some cases, the peptidase recognition amino acid sequence is inserted with a single copy. In other cases, the peptidase recognition amino acid sequence can be inserted with multiple copies, for example, one copy, two copies or three copies. In some cases, the peptidase recognition amino acid sequence is FLVIR (SEQ ID NO: 4).

[0017] In some cases, the engineered pill is encoded by a nucleic acid sequence of any one of SEQ ID NOs: 49-56.

[0018] Third, the present disclosure provides an engineered phage population comprising a plurality of phage clones of the engineered phage described herein, wherein each phage clone in the plurality of phage displays the same putative CPP on pill.

[0019] Fourth, the present disclosure describes an engineered phage library comprising a plurality of phage clones of the engineered phage described herein (i.e., phage engineered to include at least one exogenous peptidase recognition amino acid sequence in pill), wherein each phage clone in the plurality of phage also displays a putative CPP on its pill. In some cases, an engineered phage library as described herein can have a high complexity (e.g., >10 9 independent clones) or very low complexity (e.g., between 10 and 1000 independent clones as a focused library).

[0020] Fifth, the present disclosure describes a method for preparing an engineered phage library, which includes the step of modifying the pill coat protein of the phage to contain at least one copy of an exogenous peptidase recognition amino acid sequence, wherein the at least one copy of the exogenous peptidase recognition amino acid sequence contains the amino acid sequence FLVIR, as shown in SEQ ID NO:4.

[0021] Sixth, the present disclosure describes a method for screening an engineered phage library for phage clones that avoid the lysosomal compartment, comprising exposing an engineered phage library as described herein to a target cell population for a predetermined period of time to obtain an internalized engineered phage, wherein the phage in the engineered phage library comprises a CPP on a modified pIII as described herein. The method also includes a step of washing the target cell population to remove uninternalized engineered phage and obtaining a washed cell population. The method also includes a step of lysing the washed cell population to obtain a recovered internalized engineered phage. The method also includes a step of identifying the recovered internalized engineered phage as a clone that avoids the lysosomal compartment in the target cell population.

[0022] In some cases, the target cell colony is a eukaryotic cell colony. In some cases, the eukaryotic cell colony is a mammalian cell colony. In some cases, the target cell colony is a colony of pancreatic B cells, adipocytes, alveolar epithelial cells, fibroblasts, skeletal muscle cells, cardiomyocytes, CHO cells, 293 cells, CaCo2 cells or neurons (including but not limited to dorsal root ganglion (DRG) neurons and hypothalamic neurons).

[0023] In some cases, the CPP is a known CPP of the target cell population. In other cases, the CPP is a putative CPP of the target cell population.

[0024] In some cases, the method may optionally include a step of amplifying the recovered internalized engineered phage prior to the identification step.

[0025] Alternatively, the present disclosure describes a method for screening phage clones sensitive to lysosomal enzymes from an engineered phage library, comprising the step of exposing the engineered phage library as described herein to cathepsins. The method also includes the step of identifying phage clones that are cleaved or degraded in the library as being sensitive to lysosomal enzymes.

[0026] In some cases, the lysosomal enzyme is a cathepsin. In some cases, the cathepsin can be cathepsin A, B, C, D, H, L and / or S.

[0027] Seventh, the present disclosure describes a method for screening putative CPPs, comprising exposing the engineered phage library to a first target cell population for a predetermined period of time, the period of time being sufficient to allow CPP binding and phage internalization, wherein the phage clones in the engineered phage library display unique putative CPPs on modified pIII as described herein. The method also includes washing the first target cell population to remove uninternalized engineered phages and obtain a washed cell population. The method also includes lysing the washed cell population to obtain a recovered internalized engineered phage. The method also includes exposing the recovered engineered phage to a second target cell population for a predetermined period of time, to penetrate the second target cell population and amplify any recovered engineered phages that penetrate the second target cell population. The method also includes identifying the CPP attached to any amplified, recovered engineered phage.

[0028] The target cell population of the CPP disclosed herein is a eukaryotic cell population. In some cases, the eukaryotic cell population is a mammalian cell population. In some cases, the mammalian cell population is a population of pancreatic β cells, adipocytes, alveolar epithelial cells, fibroblasts, skeletal muscle cells, cardiomyocytes, CHO cells, 293 cells, CaCo2 cells, or neurons (including but not limited to dorsal root ganglion (DRG) neurons and hypothalamic neurons).

[0029] Eighth, the present disclosure describes a CPP with cytoplasmic localization rather than lysosomal localization, which includes an amino acid sequence selected from any one of SEQ ID NO: 12 to 48. Such CPPs can be used to promote active transport of therapeutic agents (and / or carriers of such therapeutic agents), including but not limited to peptides, proteins, lipid nanoparticles (LNPs), polymer lipid carriers (PLVs), oligonucleotides (e.g., mRNA, iRNA, siRNA, antisense oligonucleotides (ASOs), etc.), mAbs or fragments thereof, and small molecules that bind to intracellular targets through covalent or non-covalent bonds for therapeutic and / or diagnostic purposes.

[0030] Therefore, in certain preferred embodiments, the present invention provides methods for delivering therapeutic agents, including but not limited to interfering RNA, to inhibit the expression of target mRNA, thereby reducing the level of target mRNA in patients suffering from a disease associated with the target mRNA.

[0031] One advantage of the platform described herein is that it allows the enrichment of CPP phage clones that avoid lysosomal localization and instead have a cytoplasmic localization.

[0032] One advantage of the platform described herein is that it is free of chemical dyes and / or labels.

[0033] One advantage of the platform described herein is that it can be screened in different cell types for delivery of a cargo of interest.

[0034] One advantage of the platform described herein is that it does not require engineering of mammalian cells.

[0035] Advantages, effects, features and purposes other than those set forth above will become more apparent upon consideration of the following detailed description. The detailed description refers to the following drawings, in which:

[0036] Figure 1 The modified bacteriophage pill coat protein as described herein is shown. Lysosomal peptidase recognition amino acid sequence (in Figure 1 The N1 and N2 domains are engineered into the GS2 linker of the M13 phage pilli coat protein (denoted as "protease substrate" in the library). When directed into the lysosomal compartment by random CPP peptides displayed on specific phages in the library, the N1 and N2 domains will typically be removed by lysosomal cathepsin digestion, resulting in loss of infectivity in the bacterial amplification step. Multiple rounds of selection can be performed to remove phage clones localized to the lysosome and enrich for phage clones that are taken up by the cytoplasm. The identity of the random peptide sequence that leads to cytoplasmic localization (i.e., the cell penetrating peptide sequence) is determined by sequencing analysis.

[0037] Figure 2 Representative results are shown for the infectivity of engineered M13 phage treated with individually isolated CHO cell lysosomal extracts at pH 5.

[0038] Figure 3 Shown are the infectivity of clones A1 and H4 incubated with lysosomal extracts from CaCo2, HEK and CHO cells.

[0039] Figure 4 shows the self-delivery of NNJA CPP-siRNA in HEK, N2a and SH-SY5Y cells. The percentage of RNA remaining and cell viability were assessed. 72 hours after treatment, the percentage of RNA remaining in the cells was assessed by qRT-PCR ( Figure 4A ), and cell viability as indicated by LDH release after compound treatment was assessed in the three cell types ( Figure 4B ).

[0040] Figure 5 Shown is the assessment of lipid interactions of synthetic NNJA peptides as determined by circular dichroism (CD).

[0041] Overview

[0042] This article describes an engineered phage library based on phage M13. M13 is an example of a commonly used phage that expresses heterologous peptides and antibody fragments by phage display. The filamentous M13 assembly occurs in the bacterial inner membrane. Phage coat proteins are synthesized in the cytoplasm using bacterial protein synthesis mechanisms, and then guided to the periplasm by different signal peptides. Functional M13 phage particles contain five types of surface coat proteins, referred to as pIII (minor coat protein), pVI (minor coat protein), pVII (minor coat protein), pVIII (major coat protein) and pIX (minor coat protein). Although all five surface coat proteins have been used to display exogenous peptides on the surface of M13 particles, the minor coat protein pIII is most commonly used to anchor the peptide of interest to the phage coat surface. See "Methods in Molecular Biology," Vol178, Antibody Phage Display: Methods and Protocols (O'Brien & Aitken eds.). pIII is present in 5 copies at the proximal end of the M13 phage and plays an important role in the infectivity, assembly and stability of the phage. pIII is expressed as a 406 amino acid polypeptide and has 3 different regions: N1, N2 and C-terminal (CT) domains. See Russel et al. (2002) Introduction to Phage Biology and Display, Phage Display: A Laboratory Manual; Cold Spring Harbor Lab. Press. The N1 domain is involved in transferring viral DNA to bacterial (e.g., E. coli) hosts during infection, while the N2 domain confers host cell recognition ability by attaching to bacterial F pili. The CT domain is involved in anchoring the pIII protein to the phage coat during assembly. See Omidfar and Daneshpour (2015) Expert Opin. Drug Discov. 10: 651-669. In some cases contemplated herein, pill lacking an exogenous peptidase recognition amino acid sequence is encoded by a nucleotide sequence as shown in SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:64, SEQ ID NO:65 or SEQ ID NO:67.Likewise, in some cases contemplated herein, pill lacking an exogenous peptidase recognition amino acid sequence has an amino acid sequence as shown in SEQ ID NO:6, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:66 or SEQ ID NO:68.

[0043] The engineered phage library described herein can be used to eliminate phage clones located in the lysosomal compartment via cell transport (e.g., endocytosis) by blocking phage amplification in bacterial cells. The use of this phage library enables CPP selection by engineering an effective peptidase recognition amino acid sequence (e.g., a cathepsin recognition sequence) into at least one of the GS1 linker and / or GS2 linker of pilli, so that when the phage clone is located in the lysosomal compartment, the lysosomal protease (e.g., cathepsin) can cut the substrate and release the N1 and N2 domains. In the absence of the N1 and N2 domains, the phage loses its infectivity when exposed to bacterial cells. Specifically, by multiple rounds of selection to consume phage clones located in the lysosome, the operator can enrich for phage clones that can skip endocytosis and / or effectively avoid the endosomal-lysosomal pathway and be localized in the cytoplasmic region (see Figure 1 ).

[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the phage libraries and CPPs herein, preferred methods and materials are described herein.

[0045] Furthermore, reference to an element with the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the element. Thus, the indefinite article "a" or "an" usually means "at least one".

[0046] definition

[0047] As used herein, "about" means within a statistically significant range of one or more values, e.g., a specified concentration, length, molecular weight, pH, sequence similarity, time range, temperature, volume, etc. Such values ​​or ranges may be within a certain order of magnitude of a given value or range, typically within 20%, more typically within 10%, and even more typically within 5%. The permissible variations encompassed by "about" will depend on the system being studied and can be readily understood by those skilled in the art.

[0048] As used herein, "antisense strand" refers to a single-stranded oligonucleotide that is complementary to a region of a target sequence. Likewise, and as used herein, "sense strand" refers to a single-stranded oligonucleotide that is complementary to a region of an antisense strand.

[0049] As used herein, "cathepsin" refers to an aspartyl, cysteine ​​or serine protease that is normally activated at low pH present in lysosomes. Examples of cathepsins used herein include, but are not limited to, cathepsin A, B, C, D, H, L and / or S. It will be appreciated by those skilled in the art that the nucleotide and amino acid sequences of such cathepsins can be readily obtained using publicly available databases (e.g., GenBank and UniProt).

[0050] As used herein, "cell penetrating peptide" or "CPP" refers to a peptide of ≤40 amino acid residues that can be translocated into one or more cells without causing membrane damage and can be used as a vector for delivering therapeutic agents and / or as a carrier for transporting such therapeutic agents to intracellular targets that require cell membrane translocation. In some embodiments, CPP is a peptide of 4 to 39 amino acid residues. In some embodiments, CPP is a peptide of 4 to 30 amino acid residues. In some embodiments, CPP is a peptide of 5 to 25 amino acid residues. In other embodiments, CPP is a peptide of 7 to 20 amino acid residues. In other embodiments, CPP is a peptide of 8 to 15 amino acid residues. In other embodiments, CPP is a peptide of 8 to 10 amino acid residues.

[0051] As used herein, "complementary" or "complementarity" refers to a structural relationship between two nucleotides, nucleosides or nucleobases (e.g., on two relative nucleic acids or on relative regions of a single nucleic acid chain, such as a hairpin structure), which allows two nucleotides to form base pairs with each other. For example, the purine nucleotides of a nucleic acid complementary to the pyrimidine nucleotides of the relative nucleic acid can be base-paired together by forming hydrogen bonds with each other. Complementary nucleotides can be base-paired in a typical Watson-Crick manner, which means that adenine is paired with thymine or uracil, guanine is paired with cytosine, or base-paired in any other manner that allows the formation of a stable duplex. Similarly, two nucleic acids can have a region of multiple nucleotides that are complementary to each other to form a region of complementarity.

[0052] As used herein, "deoxyribonucleotide" refers to a nucleotide in which the hydroxyl group at the 2' position of the pentose is replaced by hydrogen, as compared to a ribonucleotide. A modified deoxyribonucleotide has one or more modifications or substitutions of atoms other than the hydroxyl group at the 2' position, including modifications or substitutions of the nucleobase, sugar or phosphate group or thereof.

[0053] As used herein, "double-stranded oligonucleotide" or "ds oligonucleotide" refers to an oligonucleotide in double-stranded form. The complementary base pairing of the double-stranded region of the ds oligonucleotide can be formed between the antiparallel sequences of the nucleotides of the covalently separated nucleic acid chains. Similarly, the complementary base pairing of the double-stranded region of the ds oligonucleotide can be formed between the antiparallel sequences of the nucleotides of the covalently connected nucleic acid chains. In addition, the complementary base pairing of the double-stranded region of the ds oligonucleotide can be formed by folding (for example, by a hairpin structure) to provide a single nucleic acid chain of complementary antiparallel nucleotide sequences that base pair together. The ds oligonucleotide can include two covalently separated nucleic acid chains that are completely double-stranded to each other. However, the ds oligonucleotide can include two partially double-stranded (for example, having overhangs at one end or both ends) covalently separated nucleic acid chains. The ds oligonucleotide can include partially complementary antiparallel nucleotide sequences, and therefore, can have one or more mispairings, which can include internal mispairings or terminal mispairings.

[0054] As used herein, "duplex" and "double-stranded region" mentioned in relation to nucleic acids (e.g., oligonucleotides) refer to structures formed by complementary base pairing of two antiparallel nucleotide sequences, whether formed by two covalently separated nucleic acid chains or by a single folded chain (e.g., by a hairpin structure). Duplexes can be formed despite the lack of complete complementarity between the two chains or the presence of abasic portions.

[0055] As used herein, "engineered" refers to artificial or synthetic or modified, especially with respect to nucleic acid sequences, amino acid sequences or organisms herein. For example, "engineered" can refer to changes in nucleic acid residues or amino acid residues, such as additions, deletions and / or substitutions, relative to a given wild-type nucleotide or amino acid sequence.

[0056] As used herein, "exogenous" with respect to a nucleotide, oligonucleotide, polynucleotide, peptide, polypeptide or protein refers to a nucleic acid sequence or amino acid sequence that is not normally found (ie, non-native) in the host cell or genome.

[0057] As used herein, "linker" more generally refers to a structure for conjugating a molecule such as a nucleotide (e.g., an oligonucleotide), a peptide, or a polypeptide to another molecule of the same or different type. As described above, some conjugates may employ one or more linker groups. The term "connection," "linker," "linker moiety," or "L" for short is used herein to refer to a linker that can be used to separate a cell penetrating peptide from an agent (e.g., a chain such as an siRNA molecule), or a linker for separating a first agent from another agent or a label (fluorescent label), such as when two or more agents are connected to form a cell penetrating peptide. The linker may be physiologically stable, or may include a releasable linker, such as an unstable linker or an enzymatically degradable linker (e.g., a linker that can be proteolytically cleaved). In some aspects, the linker may be a peptide linker. In some aspects, the linker may be a non-peptide linker or a non-protein linker. In some aspects, the linker may be a particle, such as a nanoparticle. The linker may be electrically neutral or may be positively or negatively charged. A reversible or unstable linker may include a reversible or unstable bond. In some embodiments, the linker can be "labile" or "cleavable," meaning that the linker can be cleaved (e.g., by acidic pH or enzymes). More specifically, a labile bond is a covalent bond that is less stable (thermodynamically) or breaks faster (kinetically) than other non-labile covalent bonds in the same molecule under appropriate conditions. Cleavage of an intramolecular labile bond can result in the formation of two molecules. For those skilled in the art, bond cleavage or instability is typically measured in terms of the half-life t of bond cleavage. 1 / 2 The unstable bond is discussed from the perspective of (the time required to cut half of the bonds). Therefore, an unstable bond covers a bond that can be selectively cut faster than other bonds in the molecule. Appropriate conditions are determined by the type of unstable bond and are well known in organic chemistry. Unstable bonds can be sensitive to pH, oxidizing or reducing conditions or reagents, temperature, salt concentration, the presence of enzymes (e.g., esterases, including nucleases and proteases), or the presence of added reagents. For example, an increased or decreased pH is an appropriate condition for pH unstable bonds. In other embodiments, the linker can be "stable" or "non-cleavable", which means that the linker is not cut under physiological conditions. In some embodiments, the linker is used to conjugate the therapeutic agent to a targeting ligand or delivery portion.

[0058] As used herein, "glycine / serine-rich 1 linker" or "GS1 linker" refers to the first of the two GS linkers in pill, which is located between the N-terminal 1 (N1) domain and the N-terminal 1 (N2) domain.

[0059] As used herein, "Glycine / Serine-rich 2 linker" or "GS2 linker" refers to the second of the two GS linkers in pill, which is located between the N2 domain and the C-terminal (CT) domain.

[0060] As used herein, "modified nucleotides" refer to nucleotides having one or more chemical modifications when compared to corresponding reference nucleotides selected from adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides, adenine deoxyribonucleotides, guanine deoxyribonucleotides, cytosine deoxyribonucleotides and thymine deoxyribonucleotides. The modified nucleotides can be non-naturally occurring nucleotides. The modified nucleotides can have, for example, one or more chemical modifications in their sugar, core base and / or phosphate group. Additionally or alternatively, the modified nucleotides can have one or more chemical moieties conjugated to the corresponding reference nucleotides.

[0061] As used herein, "modulate", "modulating", etc. refers to the expression of a target gene, or the level of an RNA molecule encoding a target protein or protein subunit, or the activity of a protein or protein subunit being upregulated or downregulated so that the expression, level, or activity is higher or lower than the expression, level, or activity observed in the absence of an oligonucleotide. For example, "modulation" with respect to siRNA may refer to inhibiting or downregulating the expression of a target gene or its protein product. Similarly, "modulation" with respect to saRNA may refer to stimulating or upregulating the expression of a target gene or its protein product.

[0062] As used herein, the term "NNJA" or "Ninja" referred to in connection with a CPP, an amino acid sequence encoding a CPP, or a nucleic acid sequence encoding a CPP amino acid sequence, means that the CPP and / or the amino acid or nucleic acid sequence encoding the CPP is identified by using the engineered phage-based CPP discovery platform disclosed herein. Similarly, the term "NNJA" or "Ninja" can be used to refer to the engineered phage-based CPP discovery platform disclosed herein and the CPP identified and / or characterized using the platform.

[0063] As used herein, "nucleotide" refers to an organic compound having a nucleoside (a nucleobase, such as adenine, cytosine, guanine, thymine or uracil; and a pentose, such as ribose or 2'-deoxyribose) and a phosphate group. "Nucleotide" can be used as a monomer unit of nucleic acid polymers such as deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

[0064] As used herein, "oligonucleotide" refers to a polymer to which nucleotides are connected, wherein each nucleotide can be modified or unmodified. The length of an oligonucleotide is generally less than about 100 nucleotides. An oligonucleotide can be single-stranded (ss) or double-stranded (ds). An oligonucleotide may or may not have a double-stranded region.

[0065] As used herein, "overhang" refers to the terminal nucleotide resulting from a strand or region extending beyond the end of the complementary strand that forms a duplex with the strand or region. The overhang may comprise one or more unpaired nucleotides extending from the double-stranded region at the 5' end or 3' end of a ds oligonucleotide. The overhang may be a 3' or 5' overhang on the antisense strand or sense strand of a ds oligonucleotide.

[0066] As used herein, "reduced expression" and for a gene refers to a reduction in the amount or level of an RNA transcript or protein encoded by the gene and / or a reduction in the amount or level of activity of the gene in a cell, cell colony, sample or subject when compared to an appropriate reference (e.g., a reference cell, cell colony, sample or subject). For example, when compared to cells not treated with ds oligonucleotides, the introduction of an oligonucleotide herein (e.g., an oligonucleotide having an antisense strand having a nucleotide sequence complementary to a nucleotide sequence) into a cell can result in a reduction in the amount or level of mRNA, protein and / or activity (e.g., degradation of mRNA by an RNAi pathway). Similarly, and as used herein, "reduced expression" refers to an act that results in a reduction in gene expression. Specifically, and as used herein, "reduction in expression" refers to a reduction in the amount or level of mRNA, protein and / or activity in a cell, cell colony, sample or subject when compared to an appropriate reference (e.g., a reference cell, cell colony, tissue or subject).

[0067] As used herein, "strand" refers to a single continuous sequence of nucleotides linked together by internucleotide bonds (eg, phosphodiester bonds or phosphorothioate bonds). A strand may have two free ends (eg, a 5' end and a 3' end).

[0068] As used herein, "synthetic" refers to nucleic acids or other compounds that are artificially synthesized (e.g., using a machine, such as a solid phase nucleic acid synthesizer) or that do not come from a natural source (e.g., a cell or organism) that normally produces the nucleic acid or other compound.

[0069] As used herein, "M13" refers to F-specific filamentous (Ff) phage, which is a member of the filamentous phage family. M13 is a circular single-stranded (ss) DNA of 6407 nucleotides. One nucleotide sequence of M13 can be provided as NCBI Ref. Seq. No. V00604.2 (SEQ ID NO: 1). Another nucleotide sequence of M13 is M13IX104 (SEQ ID NO: 2). However, those skilled in the art understand that more examples of M13 nucleotide and amino acid sequences can be easily obtained using publicly available databases (e.g., GenBank and UniProt).

[0070] As used herein, "pIII" or "pIII coat protein" refers to the M13 phage surface coat protein of about 406 amino acid residues (see, e.g., SEQ ID NO: 6, 60 or 62), which comprises three major domains connected by two GS linkers: N1, N2 and CT domains.

[0071] As used herein, "peptidase recognition amino acid sequence" is a sequence of about 5-9 amino acids in length, more typically about 4-7 amino acids in length, which is involved in the recognition of peptidases and the cleavage of peptides having the sequence. Many examples of peptidase recognition amino acid sequences, including those known to be recognized and cleaved by cathepsins, are well known in the art and therefore do not require detailed description herein.

[0072] As used herein, "protease" and "peptidase" are used interchangeably.

[0073] As used herein, "aRNA", "aRNA agent", "RNAa", "RNAa agent" and "RNA activator" refer to agents that contain RNA and mediate targeted activation of promoters or other non-coding transcripts of RNA transcripts through the RNA-induced transcriptional activation (RITA) complex pathway. aRNA activates, increases, regulates or upregulates expression in cells.

[0074] As used herein, "iRNA", "iRNA agent", "RNAi", "RNAi agent" and "RNA interference agent" refer to agents that contain RNA and mediate targeted cleavage of RNA transcripts through RNA interference (e.g., through an RNA-induced silencing complex (RISC) pathway). In some embodiments, the RNAi agent has a sense strand and an antisense strand, and the sense strand and the antisense strand form a duplex. In some embodiments, the sense strand and the antisense strand of the RNAi agent are 21-23 nucleotides in length. In other embodiments, the sense strand and the antisense strand can be longer, for example, 25-30 nucleotides in length, in which case the longer RNAi sequence is first processed by the Dicer enzyme. iRNA weakens, inhibits, regulates or reduces expression in cells.

[0075] As used herein, the terms "small interfering RNA (siRNA)", "siRNA molecules" or "siRNA" are used interchangeably and refer to small inhibitory RNA duplexes that induce RNA interference (RNAi) pathways. As used herein, these molecules can vary in length (typically 15-30 base pairs and optional overhangs) and have varying degrees of complementarity with their target mRNA in the antisense strand. Some, but not all, siRNAs have unpaired overhanging bases at the 5' or 3' end of the sense strand and / or antisense strand. The term "siRNA" includes a duplex of two independent strands and, unless otherwise indicated, also includes a single strand that can form a hairpin structure containing a double-stranded region, such as a short hairpin RNA ("shRNA"). Therefore, in some embodiments, the polynucleotide is a shRNA molecule, which refers to a double-stranded RNA molecule, typically 20-24 base pairs in length, similar to miRNA, and operates within the RNA interference (RNAi) pathway. It is intended to use complementary nucleotide sequences to interfere with the expression of specific genes by degrading mRNA after transcription and preventing translation. Small interfering RNA may also be referred to in the art as, for example, short interfering RNA or silencing RNA.

[0076] As used herein, "subject" refers to any mammal, including cats, dogs, mice, rats, and primates, as well as humans. Preferably, the subject refers to humans. In addition, "individual" or "patient" can be used interchangeably with "subject".

[0077] As used herein, "treatment" or "treating" refers to all processes in which the lesions or disease progression disclosed herein may be slowed down, controlled, delayed or stopped, or the lesions or disease symptoms may be improved, but does not necessarily mean the complete elimination of all lesions or disease symptoms. Treatment includes the administration of nucleic acids or vectors or compositions for the treatment of a disease or condition in a patient (particularly a human). In addition, additional disclosures are contemplated to achieve the desired efficacy or results based on the data we have and our draft labeling language.

[0078] As used herein, "vector" refers to a nucleic acid molecule that can transport another nucleic acid sequence (or multiple nucleic acid sequences) connected thereto to a host cell or genome. One type of vector is a "plasmid", which refers to a circular DNA loop, usually double-stranded (ds), to which additional DNA fragments can be connected. Another type of vector is a viral vector, in which additional DNA fragments can be connected to the viral genome. Some vectors can replicate autonomously in the host cell into which they are introduced (for example, bacterial vectors with bacterial replication origins). In addition, when combined with appropriate control sequences such as promoter and operator sequences and replication initiation sites, some vectors can guide the expression of genes operably connected thereto (for example, genes encoding exogenous peptides or target proteins). Such vectors are generally referred to as "expression vectors", and may also include a multiple cloning site for inserting genes encoding target proteins. Alternatively, genes encoding target peptides or proteins can be introduced by site-directed mutagenesis techniques such as Kunkel mutagenesis. See, for example, Handa et al., Rapid and Reliable Site-Directed Mutagenesis Using Kunkel's Approach, Methods in Molecular Biology, vol 182: In Vitro: Mutagenesis Protocols, 2nd edition).

[0079] Composition

[0080] The compositions herein include engineered phages, particularly engineered phages based on M13. For example, conventional details about M13 and phage display can be found in International Patent Application Publication No. WO 2017 / 091467.

[0081] Compositions herein also include engineered pill coat proteins.

[0082] The compositions herein also include an engineered phage library, particularly an engineered phage library based on M13. Those skilled in the art will recognize that an engineered phage library of the type disclosed herein can be created for a specific target cell population, which has a high diversity relative to the screened putative CPP (e.g., a primary library) or has a lower diversity relative to the screened putative CPP or the optimized novel CPP (e.g., a secondary or enrichment library). In some cases, the diversity of the engineered phage library is disclosed herein.

[0083] The compositions disclosed herein include novel CPPs. In some embodiments, the novel CPPs are peptides of 2 to 10 amino acid residues. In other embodiments, the CPPs are peptides of 5 to 10 amino acid residues. In other embodiments, the CPPs are peptides of 8 to 10 amino acid residues. The compositions herein also include CPPs, particularly CPPs with 9 amino acid residues.

[0084] method

[0085] The methods herein include methods of making engineered phages, particularly M13-based engineered phages and libraries comprising the engineered phages.

[0086] Kunkel mutagenesis is well known in the art and need not be described in detail herein. See, for example, Handa et al. (2002), "Rapid and Reliable Site-Directed Mutagenesis Using Kunkel's Approach" In: In Vitro Mutagenesis Protocols. Methods in Molecular Biology, vol182. (Braman ed., Humana Press, Totowa, NJ).

[0087] The methods herein also include methods for screening engineered phage that can avoid lysosomal localization.

[0088] In some cases, the method of screening an engineered phage or an engineered phage library for phage that is sensitive to a lysosomal enzyme or that can avoid lysosomal localization comprises the following steps:

[0089] (a) providing an engineered phage library as disclosed herein;

[0090] (b) exposing the engineered phage library to a lysosomal enzyme for a predetermined period of time to obtain cleaved engineered phage and uncleaved engineered phage; and

[0091] (c) Phage that are cleaved by lysosomal enzymes are identified as sensitive, or phage that avoid lysosomal localization based on the lack of cleavage.

[0092] In some cases, the lysosomal enzyme is a cathepsin, such as cathepsin A, B, C, D, H, L, and S.

[0093] In some cases, the methods provided herein include a method for screening putative cell penetrating peptides (CPPs) for a specific type of cell, the method comprising the following steps:

[0094] (a) providing an engineered phage library according to any one of claims 14 to 15;

[0095] (b) exposing the engineered phage library to a first target cell population for a predetermined period of time to obtain internalized engineered phage;

[0096] (c) washing the first target cell population to remove uninternalized engineered phage and obtain a washed target cell population;

[0097] (d) lysing the washed first target cell population and obtaining recovered internalized engineered phage;

[0098] (e) exposing the recovered internalized engineered phage to a second target cell population for a predetermined period of time to infect the second target cell population and obtain amplified, recovered internalized engineered phage; and

[0099] (f) Identifying clones from the amplified, recovered engineered phage that avoid the lysosomal compartment in the first target cell population.

[0100] In some cases, the first target cell population is a eukaryotic cell population.

[0101] In some cases, the first target cell population is a mammalian cell population.

[0102] In some cases, the first target cell population is selected from pancreatic β cells, adipocytes, alveolar epithelial cells, fibroblasts, skeletal muscle cells, cardiomyocytes, CHO cells, 293 cells, CaCo2 cells, or neurons, including but not limited to dorsal root ganglion (DRG) neurons and hypothalamic neurons.

[0103] The methods herein also include methods of screening for putative CPPs using the engineered phage or libraries herein.

[0104] The method may also include the following steps: exposing the recovered engineered phage to a second target cell population in a predetermined time period to screen for internalization of the second target cell population, and amplifying any recovered engineered phage that penetrates the second target cell population. When it comes to the second target cell type, those skilled in the art will recognize that there are many possible useful selection strategies according to the desired characteristics in any novel CPP. In some cases, for example, internalization peptide-phages recovered can be selected by positive selection for the first target cell population and then taking out the recovered internalization peptide-phages to further select for internalization of the second target cell population, thereby jointly targeting the internalization of the first and second target cell populations. In other cases, those skilled in the art can perform reverse selection (negative selection) for the first target cell population, take out the peptide-phages remaining outside the cell, and perform internalization selection (positive selection) for the second target cell population. In other cases, the screening method may include positive selection for internalization of the first and second target cell populations in parallel arms, and then compare the differences (subtraction) or consistency (consensus) of the peptide hit results.

[0105] In some cases, the first and second target cell populations are eukaryotic cell populations.

[0106] In some cases, the first and second target cell populations are mammalian cell populations.

[0107] In some cases, the first and second target cell populations are each selected from pancreatic β cells, adipocytes, alveolar epithelial cells, fibroblasts, skeletal muscle cells, cardiomyocytes, CHO cells, 293 cells, CaCo2 cells, or neurons, including but not limited to dorsal root ganglion (DRG) neurons and hypothalamic neurons.

[0108] The method further comprises the steps of exposing the recovered engineered phage to a population of bacterial cells for a predetermined period of time to infect the population of bacterial cells and amplifying any recovered engineered phage that infects the target cell population.

[0109] The following non-limiting examples are offered for purposes of illustration and not limitation.

[0110] Generation of engineered M13 phage library

[0111] Example 1: Engineering of a cathepsin-cleavable substrate into the GS1 and / or GS2 linker of the bacteriophage pill coat protein.

[0112] method:

[0113] Cells and reagents: Chinese hamster ovary (CHO-2F9, in-house source; CHO) cells were cultured at 37°C, 5% CO 2Expi293 (293; Life Technologies) cells were cultured in suspension in an in-house prepared culture medium (M9195 + 12 mM L-glutamine). 2 Adherent colon cancer (CaCo2; in-house source) cells were cultured in suspension in culture medium (Cat. No. A14351-01; Gibco) at 37°C and 5% CO 2 Cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with L-glutamine, 10% heat-inactivated (HI) FBS, 1 mM sodium pyruvate, and 25 mM HEPES. Adherent HEK293 (HEK) cells were grown in minimal essential medium (MEM) supplemented with 10% HI FBS, 1x non-essential amino acids, 1 mM sodium pyruvate, and 0.075% sodium bicarbonate and used for microscopy imaging and cytotoxicity purposes. If not specified, cell culture reagents were purchased from Gibco.

[0114] Antibodies: anti-EEA1 (Cat. No. ab2900; Abcam); anti-LAMP1 (Cat. No. ab24170; Abcam).

[0115] For confocal imaging, anti-M13-Alexa 647 (in-house source), anti-LAMP 1 (Cat. No. 9091; Cell Signaling); anti-F-actin-DyLight488 (Cat. No. PI21833; ThermoFisher); DAPI (Cat. No. D1306; Invitrogen); Alexa Fluor 488, Alexa Fluor 568, and Alexa Fluor 647-conjugated fluorescent secondary antibodies (Life Technologies).

[0116] Subcellular fractionation: Cytoplasmic and endosomal extracts were prepared according to the manufacturer's protocols of ThermoFisher Scientific (Cat. No. 89842) and Invent Biotechnologies (Cat. No. #ED-028), respectively. The starting number of cells for one cytoplasmic extraction was 5 × 10 6 cells, and the starting number of cells for one endosomal extraction was 3×10 7 The lysosome isolation of different cell types was optimized based on the Abcam kit (Cat. No. ab234047) for the homogenization step and increased isolation scale. The starting number of cells for one lysosome isolation was 2×10 8 cells.

[0117] Cathepsin enzymatic cleavage assay: Six fluorescent peptide substrates were purchased from R&D Systems, Bachem or Chemimpex. Cathepsins B and L share the same fluorescent peptide substrate, while the other five cathepsins recognize and cleave specific fluorescent peptide substrates. The corresponding peptide substrates for each cathepsin are as follows: cathepsin A (Cat. No. ES005; R&D Systems), cathepsin B / L (Cat. No. ES008; R&D Systems), cathepsin C (Cat. No. I-1215; Bachem), cathepsin D (Cat. No. ES001; R&D Systems), cathepsin H (Cat. No. 05859; Chemimpex) and cathepsin S (Cat. No. ES002; R&D Systems). Cleavage efficiency of single lysosomal isolates from different cell types using peptide substrates. 5 μl of 200 μM peptide substrate was incubated with 5 μl lysosomal extract in citrate buffer (pH 5) for 30 minutes at 37°C. Fluorescence emission of each peptide substrate is detected at a specific wavelength, depending on the attached fluorophore. Fluorescence levels are normalized by subtracting the background fluorescence produced by the peptide substrate in citrate buffer alone. The higher the fluorescence signal detected, the higher the level of enzyme substrate cleavage activity of the specific cathepsin enriched from the lysosomes.

[0118] Engineering peptidase-cleavable substrates into the GS1 and / or GS2 linkers of pill: Phage clones with cleavable substrates were generated using wild-type M13 phage vectors or recombinant engineered variants thereof (see, e.g., International Patent Application Publication No. WO 2017 / 091467, U.S. Patent Application Publication No. 2018 / 0327480 and / or Afshar, S. et al., Protein Engineering, Design and Selection, 2020, vol. 33, pp. 1-8). The uracil-containing ss DNA (du-ssDNA) of the M13 IX104 phage vector was prepared using the E. coli strain RZ1032 (Cat. No. 39737, ATCC) lacking functional dUTPase and uracil glycosylase.

[0119] Design the oligonucleotide sequence of the FLVIR sequence (SEQ ID NO:4) encoding 5 residues, and anneal the corresponding reverse complementary oligomer to different positions in the pIII GS2 joint region of the du-ssDNA IX104 vector by Kunkle mutagenesis.Electrocompetent Escherichia coli DH1 0B cells (Cat. No. 18290015, Invitrogen) are used for transformation.Randomly select the transformant pool and sequence to confirm the presence of substrate and determine the substrate position.40 phage clones were amplified overnight at 37°C, on LB plates, in the presence of freshly grown XL-1 blue cells (in-house source).The next day, polymerase chain reaction (PCR) was performed to amplify the gene III sequence, which encodes the pIII of each phage clone.Then, the PCR product was sequenced to confirm the presence of the corresponding cleavable substrate in the GS2 joint.

[0120] The overnight phage cultures described above were grown for ten rounds to assess substrate sequence retention for each phage clone. Sanger sequencing was performed after each round of phage culture to confirm substrate insertion. The final phage clones with substrate insertion were then assessed for cathepsin accessibility by incubation with lysosomal extracts from different mammalian cell lines.

[0121] result:

[0122] In order to maximize the attenuation effect of phage infectivity, the FLVIR sequence (SEQ ID NO: 4) was inserted into the GS2 linker of pilli to completely remove the N1 and N2 domains after cathepsin digestion. By Kunkle mutagenesis, the FLVIR sequence (SEQ ID NO: 4) was randomly inserted into the linker region in single or multiple copies to generate 40 phage clones. In order to ensure that the substrate sequence remained in place after multiple rounds of selection, 10 rounds of overnight phage culture were completed and sequencing was performed after each round to confirm. After 10 rounds of culture, 18 unique phage clones were harvested, which had 1, 2 or 3 copies of FLVIR (SEQ ID NO: 4) inserted into the linker site (Table 1). The gray box indicates the position of the inserted substrate sequence. Both GS1 and GS2 linkers are glycine (Gly) and serine (Ser)-rich sequences with high nucleotide sequence similarity. Therefore, in addition to the GS2 linker, a small amount of FLVIR sequence (SEQ ID NO: 4) also appeared in the GS1 linker.

[0123] Table 1: Location of FLVIR sequences in pill of engineered M13 phage.

[0124]

[0125] The accessibility of the engineered GS2 linker to active cathepsins (confirmed by fluorescent cleavage assay) of 18 phage clones was assessed by incubating the phage clones with CHO cell lysosomal extracts at 37°C. The assessment was repeated four times with independently isolated lysosomes in an acidic environment (approximately pH 5). A trend of reduced phage infectivity was observed to varying degrees among the 18 phage clones, while naked phages maintained full infectious capacity (e.g., Figure 2 Representative figures in Figure 2 are shown). Among all phage clones, A1 and H4 were highly consistent, representing high (if not complete) infectivity and low infectivity (reduced by 98%), respectively (A1 clone, mean = 114.8%, SEM = 19.11%; H4 clone, mean = 2%, SEM = 0.7%; naked phage, mean = 107%, SEM = 5.9%, n = 4) (data not shown). In addition to the difference in the engineered GS2 linker, both phage clones contain the same backbone as the naked phage (NP), indicating that the engineered substrate in the H4 clone is very effective.

[0126] In addition to CHO cells, the accessibility of clones A1 and H4 to active cathepsins was further assessed in lysosomal extracts from CaCo2 and HEK293 cells. Although the fluorescent cleavage assay indicated slight changes in the cathepsin profiles in the different cell types (Table 2), lysosomal cathepsins continued to recognize and cleave the FLVIR sequence (i.e., SEQ ID NO: 4) engineered in the clone H4 phage, resulting in significantly lower infectivity after incubation at 37°C for 30 minutes (see Figure 3 ). CaCo2 lysosomes: clone A1 (mean = 79.83%, SEM = 9.5%) vs. H4 (mean = 34.63%, SEM = 13.5%), p = 0.22, n = 3. HEK293 lysosomes: clone A1 (mean = 75.1%, SEM = 9.7%) vs. H4 (mean = 9.5%, SEM = 1.6%), p = 0.018, n = 3. CHO lysosomes: clone A1 (mean = 95.58%, SEM = 13.8%) vs. H4 (mean = 2.738%, SEM = 0.8%), p < 0.0001, n = 6.

[0127] Table 2. Activity assessment of lysosomal isolates from different cell types by cathepsin fluorogenic substrates

[0128]

[0129] Example 2: Phage display library construction and CPP selection.

[0130] method:

[0131] Cells and reagents: Neuro2a (N2a) cells were cultured at 37°C, 5% CO 2 SH-SY5Y cells were cultured in DMEM (Cat. No. 10-017-CV, Corning) supplemented with 10% HI FBS (Cat. No. 35-011-CV, Corning). SH-SY5Y cells were cultured at 37°C and 5% CO 2 HEK and CaCo2 cells were cultured in Eagle's Minimum Essential Medium (EMEM) (Cat. No. MT10009CV, Corning) and Ham's F12 Medium (Cat. No. 12-615F, Lonza) at a ratio of 1:1 supplemented with 10% HI FBS. HEK and CaCo2 cells were cultured as described above.

[0132] Phage display library: Generate a peptide phage library based on the selected backbone structure of the desired M13 phage vector (e.g., in an 8+11 vector based on the selected backbone structure of an IX104 phage vector) with a cathepsin-cleavable substrate insert in a GS2 linker.

[0133] A library of 9-residue oligonucleotides encoding random amino acid sequences (9NNK) was designed so that the random NNK regions were flanked by nucleotides complementary to the vector. Using Kunkel mutagenesis, the 5′-phosphorylated reverse complementary oligomers were annealed to the du-ssDNA 8+11 vector and extended to form dsDNA (Sidhu et al., (2000) Methods Enzymol. 328: 333-363). Specifically, based on the backbone structure of phage clone H4, a random peptide library of 9 amino acids in length (i.e., 9NNK) was constructed and displayed at the N-terminus of phage pill. The diversity of the H4_9NNK library was approximately 7x10 8 pfu.

[0134] Electrocompetent E. coli DH1 0B cells were used for transformation. Pools of transformants were titrated to determine the diversity of the library. Phages were then amplified overnight at 37°C on LB plates in the presence of freshly grown XL-1 blue cells. The next day, phages were eluted from the plates, precipitated, titrated and stored at -80°C in the presence of 50% glycerol until use.

[0135] Before applying the engineered phage library to mammalian cells, the complete medium was replaced with serum-free medium and the cells were incubated at 37 °C for 1 h. For the initial selection, 10 12 phages with 10 as different selection arms 7Each cultured cell was incubated for 1 hour at 37°C in a tissue culture incubator (on a rotator for suspended cells). This allowed internalization to occur guided by the displayed peptide on the phage. During internalization, if a phage particle displaying a specific peptide penetrates into the cell and reaches the lysosome through cellular trafficking, one or more FLVIR sequences (SEQ ID NO: 4) in the phage pill are accessed and cleaved by lysosomal cathepsins, which results in loss of phage infectivity.

[0136] After internalization, cells were gently washed once with cold phosphate buffered saline (PBS), and then washed for 5 minutes with cold, low pH stripping buffer (for CHO cells, the culture medium was adjusted to pH 2.5; for 293 and CaCo2 cells, 100 mM glycine, 150 mM NaCl, pH 2.5) and repeated twice. Then, cells were immediately washed 3 times with cold PBS. Suspended cells were centrifuged at 300 x g for 5 minutes at 4 ° C, while adherent cells were scraped on ice and directly entered the next step. The washed cells were gently lysed using cytoplasmic extraction reagent (ThermoFisher Scientific) to collect phage particles in a volume of about 1.5 mL. Phages from serum-free medium combined with the first PBS wash (considered extracellular) and cytoplasmic extracts (considered intracellular) were titrated separately to assess the phage recovery rate compared to the input amount. Phages recovered from the cytoplasmic region were plated onto large LB plates (Cat. No. L6100, Teknova) along with 5 mL of freshly grown mid-logarithmic XL-1 blue cells and 40 mL of top agar for amplification. The plates were incubated overnight at 37°C. The next day, the LB plates were first equilibrated to room temperature and incubated at room temperature by incubating with 30 mL of phage suspension buffer (100 mM NaCl, 8.1 mM MgCl 2 , 50 mM Tris-HCl, pH 7.5) for 2 h to elute the phages.

[0137] Then, the surface of the plate was gently scraped and the phage eluate was collected. The eluted phage sample was centrifuged, precipitated and titrated for subsequent rounds of selection. Five rounds of selection were performed. From the 3rd round output (ORD) to the entire selection completion period, phage plaques were randomly picked, eluted, PCR amplified and sequenced by Sanger sequencing. The amplified phage samples of ORD 3-5, which were used as the 4th-6th round input (IRD), were analyzed by next generation sequencing (NGS) to identify peptide sequences and their frequency of occurrence.

[0138] Sanger sequencing: The amplicons were first purified using exonuclease I and Fast AP. The purified PCR products were used as DNA templates for Big Dye Terminator 3.1 cycle sequencing chemistry. The sequencing reactions were then purified with Seq DTR MagBind beads and loaded onto the Bioanalyzer3730XL for sequencing by capillary electrophoresis.

[0139] NGS: Amplicons undergo a 2-step PCR process. The first PCR step is to add SBS sites for Illumina sequencing primers, and the second PCR step is to add Nextera Indexes to allow sample de-multiplexing. Both PCR steps are purified using MagBind RxnPurePlus beads at a 1.8x ratio. The purified PCR products are quantified by qPCR using ViiA 7 and Bioanalyzer 2100 fragment analyzers. The samples are then combined in equimolar ratios and denatured according to Illumina's MiSeq system denaturation and dilution guidelines. The samples are loaded onto the MiSeq at a concentration of 12.5pM and spiked with 20% PhiX. The running conditions of the MiSeq are 130 single-direction cycles and 1M sequence readings by V2 Nano ReagentKit.

[0140] Immunocytochemistry and confocal microscopy: After the washing steps, cells were fixed with 4% paraformaldehyde (PFA) on ice for 20 minutes. Fixed cells were washed three times with PBS to remove any excess PFA, and then blocked for 1 hour in 3% bovine serum albumin (BSA) in Tris-buffered saline (TBS) containing 0.2% Triton X-100, and antibody staining was performed in TBS containing 0.2% Triton X-100. The primary antibody was incubated with the cell samples overnight at 4°C. After PBS washing, signal detection was performed using species-specific Alexa Fluor 488, Alexa Fluor 568, and / or Alexa Fluor 647-conjugated secondary antibodies (Life Technologies; Grand Island, NY).

[0141] Imaging analysis was performed on a confocal microscope using a laser scanning microscope 800NLO (Zeiss) equipped with an argon laser. The primary antibodies were as follows: anti-M13-Alexa647 (internal source), anti-LAMP1, anti-F-actin-DyLight488 and DAPI. Controls treated with secondary antibodies showed only negative or undetectable signals.

[0142] Lipid interaction assessment by circular dichroism (CD): Secondary structure characterization of CPPs was performed in the presence of ultrapure water and 1X HBS-N buffer. Similarly, CD spectra of CPP structural states were collected in the presence of a model lipid membrane (POPC) using a JASCO-1500CD spectrometer. 1 mg / mL peptide was transferred to a 0.02 cm path length quartz cuvette for far UV-CD measurements. POPC was added in equal concentrations (w / v). All measurements were completed at room temperature (20°C). Spectra were collected in the wavelength range of 250-190 nm. In addition, peptide spectra were corrected by subtracting appropriate controls. Secondary structure quantitative analysis was completed using SSE multivariate analysis.

[0143] Far-UV-CD parameters during spectral measurements: CD spectral measurements were performed in standard mdeg mode. Scan speed: 50 nm / min; response: 2 s; bandwidth: 2 nm; [Q] ellipticity was converted to mean residual ellipticity using the following formula:

[0144] [q] MRE =q*MRW / cl,

[0145] Where MRW = (molecular weight of protein or peptide / number of peptide bonds in protein).

[0146] Circular dichroism spectra were deconvoluted to calculate % helical, beta sheet and random coil structures by CD multivariate SSE in JASCO-1500. CD instrument ID: M610823.

[0147] Peptide synthesis and conjugation: Synthetic peptides were ordered from CPC scientific with 90-95% purity. Chemical conjugation (e.g. CPP with siRNA) was performed in-house. NNJA peptides in monomeric or dendrimer form were conjugated to siRNA targeting the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene (designed in-house, synthesized by Biosynthesis) at the C-terminus of the peptides by click chemistry.

[0148] NNJA-siRNA knockdown assay: 10,000 cells such as HEK, N2a and SH-SY5Y cells were plated in Accel1 medium and then treated with compounds (siRNA control, NNJA-siRNA or cholesterol-siRNA). The concentration of the test compound started at 2 μM and then diluted 1:5. The cells were then incubated at 37°C, 5% CO 2The cells were incubated for 72 hours at 4 °C. The knockdown efficiency of the compound (i.e., NNJA-siRNA) was evaluated by qRT-PCR using Cells-to-Ct, followed by TaqMan (Cat. No. A25603, ThermoFisher) and HPRT primers / probes. Cell activity was evaluated by CytoTox 96 non-radioactive cytotoxicity assay (Cat. No. G1780, Promega). Statistical analysis was generated using 3-parameter curve fitting in Prism.

[0149] Statistics: Unless otherwise stated, statistical analyses were performed on GraphPad Prism (version 9.1.1) using standard error of the mean (SEM), two-way ANOVA analysis and multiple comparison tests. Statistical results (eg, p-values) are described in the figure legends and use 95% confidence intervals.

[0150] result:

[0151] As the selection rounds proceed, the output / input ratio of phage titer recovery in each round of selection increases (Table 3). The results show that peptides displayed on cell-permeable phages are gradually enriched in each cell type through a cell-based panning process. By Sanger sequencing of randomly selected plaques, the occurrence of 20 naturally occurring amino acids at each of the 9 positions from the original library before cell-based selection was tested, showing that the frequency of amino acids observed at each position was quite equal, with no residue bias (data not shown).

[0152] The same analysis was then performed on the enriched CPPs from subsequent selection rounds. The peptide sequences identified from randomly picked phage plaques from the three selection arms were combined and summarized by their selection rounds (ORD3, 4, and 5) (data not shown). Overall, patterns began to emerge after three rounds of selection, and specific residues were preferred at specific positions. For example, methionine (Met) and leucine (Leu) dominated the first position (N-terminus), while serine (Ser) and threonine (Thr) shared the main frequency at the second position. Proline (Pro) repeats accumulated in the middle and ends of the peptide sequence. When the three selection arms from ORD5 were evaluated separately, the bias pattern was also consistent, but with cell type preference (data not shown), such as at positions 3, 4, and 6. Surprisingly, all CPPs found from the three selection arms were linear and had extremely high isoelectric point (PI) values ​​(most PIs were ~9-12) (data not shown).

[0153] Table 3: Percent recovery of phage titers from the cytoplasmic region after each round of selection. Output phage titers were normalized to input titers and shown as percent recovery.

[0154]

[0155] To confirm the internalization of CPP, the internalization of phage samples from IRD6 (amplified ORD5) in HEK cells was first tested by confocal microscopy. Before imaging, IRD6 phages from 3 selection arms were added to adherent HEK cells together with 2 negative controls (e.g., naked phage and natural phage libraries) and incubated at 37 ° C for 1 hour. Under confocal microscopy, the penetrated phage particles were detected by anti-M13 antibody. The cell membrane was outlined by staining with filamentous actin antibody, and the nucleus was detected by DAPI. The anti-M13 antibody signal detected from the control group was the lowest, indicating that neither naked phage nor natural phage library itself penetrated HEK cells. In the enriched CPP group generated by selection, the signal intensity of internalized phage particles was mainly detected in the cytoplasmic region and significantly increased. Peptide-phage selected from 293 cells (IRD6_293) showed higher internalization levels in HEK cells compared to peptide-phage selected from CHO and CaCo2 cells, indicating cell type preference.

[0156] In addition, the subcellular localization of internalized phage particles from the IRD6_293 pool in HEK cells was evaluated using the z-stack function under a confocal microscope. The phage signal detected by the anti-M13 antibody was located in the cytoplasmic region and was not co-localized with EEA1 (early endosome) or LAMP1 (lysosome) staining. The results showed that the IRD6_293 peptide appeared to enter the cytoplasmic region of the HEK cells and further verified the mechanism of action of the novel phage library and selection process. Comparable results were observed using the same phage samples internalized in CaCo2 cells. Enhanced phage signals were detected in the cytoplasmic region and were not co-localized with EEA1 or LAMP 1 staining.

[0157] Among the internalized peptides with high occurrence frequency, 37 NNJA peptides with the highest occurrence and / or enrichment rate were selected from the three selection arms based on NGS analysis and constructed into homogeneous (monoclonal) NNJA-phage samples (i.e., NNJA peptides). Some NNJA peptide sequences were shared by the three cell selection arms, while others were cell type-preferred or specific (Table 4), indicating that different internalization mechanisms of peptides were used in different cell types. The penetration and subcellular localization of purified peptide-phages in HEK and CaCo2 cells were evaluated by confocal imaging. Homogeneous NNJA peptides on phages were added to cells and internalized for 1 hour at 37°C. Cells were washed and surface-bound phages were fully stripped, followed by immunocytochemical staining and confocal microscopy imaging. The different cytoplasmic internalization levels of NNJA peptides on phages are summarized in Table 4. According to NGS analysis, the internalization levels of NNJA peptides in HEK and CaCo2 cells were generally consistent with the occurrence levels of cell type selection, respectively (data not shown).

[0158] Table 4: Putative CPP amino acid sequences and cell type cytoplasmic internalization.

[0159]

[0160] The peptide NNJA_15 on the phage was further evaluated by confocal microscopy to evaluate penetration in additional cell types, including N2a and SH-SY5Y cells. The phage samples were introduced into the target cells and allowed to internalize for 1 hour at 37°C. Then, the cells were processed for confocal imaging and analysis as described previously. In both N2a and SH-SY5Y cells, moderate levels of NNJA-15 on the phage were detected in the cytoplasmic region by anti-M13 antibodies, and there was no co-localization with LAMP1 staining. The results show that in addition to the cell types initially screened for it, the NNJA peptide can also penetrate into the cell types.

[0161] To evaluate whether the NNJA peptides as synthetic peptides can further deliver payloads in mammalian cells, the selected peptides were conjugated with siRNA targeting the HPRT gene for evaluation of self-delivery. In addition to the monomeric form of the NNJA peptide, dendrimer peptides were also evaluated, which mimic the multiple copies and structure of the peptide displayed on phage. The compounds were introduced into various cell types (e.g., HEK, N2a, and SH-SY5Y cells), and the knockdown efficiency of the HPRT gene was studied, expressed as the percentage of RNA remaining after 72 hours (see Figure 4AHPRT siRNA conjugated to cholesterol served as a positive control, and naked siRNA and non-targeting control (NTC) siRNA-cholesterol served as negative controls. Overall, NNJA dendrimers provided higher penetration levels, resulting in higher siRNA knockdown, and some of the dendrimers tested achieved ~80% gene reduction with single-digit nanomolar half-maximal inhibitory concentrations (IC 50 ) values ​​(not shown). The results suggest that the multivalency of the peptide contributes to penetration. Interestingly, the monomeric form of NNJA_1 facilitates siRNA entry and achieves higher knockdown in HEK and N2a cells compared to its dendrimer counterparts, while the dendrimers perform better in SH-SY5Y cells. NNJA_5 monomers provide better penetration for siRNA delivery in all three cell types compared to their dendrimer counterparts.

[0162] Figure 4B Cellular activity measured by lactate dehydrogenase (LDH) release is shown. The NNJA peptide did not induce significant cell death compared to the control group. In N2a cells, lower activity was observed in the NNJA dendrimer group; however, activity was restored at higher treatment concentrations of peptide-siRNA. The activity indicated by LDH release may not reflect true cytotoxicity, but rather mild LDH release under certain treatment conditions.

[0163] To investigate the potential mechanism of action of the NNJA peptides, four highly internalized NNJA peptides were evaluated as synthetic monomeric peptides for potential lipid interactions in the presence of liposomes by circular dichroism (CD) spectroscopy. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) is one of the most common liposomes representing the lipid component of the plasma membrane of mammalian cells and was used for biophysical evaluations in this assay. All four peptides presented similar secondary structural features but with different secondary structure content (e.g. helices, sheets and turns (data not shown)). Upon interaction with POPC, significant changes in intensity and CD signal maxima were observed in the secondary structural features of NNJA_19 (shown as dashed lines), but not for NNJA_1, NNJA_5 or NNJA_15. Therefore, a direct interaction with the lipid bilayer was shown to be the possible penetration mechanism of NNJA_19, while NNJA_1, NNJA_5 or NNJA_15 were shown to utilize different mechanisms to enter the cytoplasmic region, such as the endocytic pathway (see Figure 5 ).

[0164] Sequence Listing

[0165] The following nucleic acid and / or amino acid sequences are referred to in this disclosure and are provided below for reference.

[0166] SEQ ID NO: 1—Wild-type M13 nucleic acid sequence

[0167]

[0168] SEQ ID NO: 2—M13IX104 nucleic acid sequence

[0169]

[0170] SEQ ID NO: 3 - Engineered M13IX104 nucleic acid sequence

[0171]

[0172] SEQ ID NO: 4—Artificial amino acid sequence

[0173] FLVIR

[0174] SEQ ID NO: 5-1M13pIII nucleic acid sequence of X104

[0175]

[0176] SEQ ID NO: 6-1M13pIII amino acid sequence of X104

[0177] AETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVVVCTGDETQCYGTWVPIGLAIPENEGGGSEGGGSEGGGSEGGGTKPPEYGDTPIPGYTYINPLDGTYPPGTEQNPANPNPSLEESQPLNTFMFQNNRFRNRQGALTVYTGTVTQGTDPVKTYYQYTPVSSKAMYDAYWNGKFRDCAFHSGFNED LFVCEYQGQSSDLPQPPVNAGGGSGGGSGGGSEGGGSEGGGSEGGGSEGGGSGGGSGSGDFDYEKMANANKGAMTENADENALQSDAKGKLDSVATDYGAAIDGFIGDVSGLANGNGATGDFAGSNSQMAQVGDGDNSPLMNNFRQYLPSLPQSVECRPFVFSAGKPYEFSIDCDKINLFRGVFAFLLYVATFMYVF STFANILRNKES

[0178] SEQ ID NO: 7-1GS1 linker nucleic acid sequence of X104

[0179] ggtggtggctctgagggtggcggttctgagggtggcggttctgagggtggcggta

[0180] SEQ ID NO: 8-1 GS1 linker amino acid sequence of X104

[0181] GGGSEGGGSEGGGSEGGG

[0182] SEQ ID NO: 9-1 GS2 linker nucleic acid sequence of X104

[0183] ggcggcggctctggtggtggttctggtggcggctctgagggtggtggctctgagggtggcggttctgagggtggcggctctgagggaggcggttccggtggtggctctggttccggt

[0184] SEQ ID NO: 10-1X104 GS2 linker amino acid sequence

[0185] GGGSGGGSGGGSEGGGGSEGGGGSEGGGGSGGSGSG

[0186]

[0187] SEQ ID NO: 12—Artificial amino acid sequence (NNJA_1)

[0188] MSTRGPTPA

[0189] SEQ ID NO: 13—Artificial amino acid sequence (NNJA_2)

[0190] MTAPAPGLQ

[0191] SEQ ID NO: 14—Artificial amino acid sequence (NNJA_3)

[0192] MTSSSDLRL

[0193] SEQ ID NO: 15—Artificial amino acid sequence (NNJA_4)

[0194] LSSRTTYQ

[0195] SEQ ID NO: 16—Artificial amino acid sequence (NNJA_5)

[0196] MT SKNTQIG

[0197] SEQ ID NO: 17—Artificial amino acid sequence (NNJA_6)

[0198] MSHVGFETT

[0199] SEQ ID NO: 18—Artificial amino acid sequence (NNJA_7)

[0200] MQPMGSTAS

[0201] SEQ ID NO: 19—Artificial amino acid sequence (NNJA_8)

[0202] MTPSRLPPS

[0203] SEQ ID NO: 20—Artificial amino acid sequence (NNJA_9)

[0204] MSKQNYHVV

[0205] SEQ ID NO: 21—Artificial amino acid sequence (NNJA_10)

[0206] MAGYRSAVN

[0207] SEQ ID NO: 22—Artificial amino acid sequence (NNJA_11)

[0208] MTTKHVATQ

[0209] SEQ ID NO: 23—Artificial amino acid sequence (NNJA_12)

[0210] MTRT STEPT

[0211] SEQ ID NO: 24—Artificial amino acid sequence (NNJA_13)

[0212] MTTPNPKVR

[0213] SEQ ID NO: 25—Artificial amino acid sequence (NNJA_14)

[0214] LTRQTNLEV

[0215] SEQ ID NO: 26—Artificial amino acid sequence (NNJA_15)

[0216] SSRPPIVTP

[0217] SEQ ID NO: 27—Artificial amino acid sequence (NNJA_16)

[0218] YTRPMSAPN

[0219] SEQ ID NO: 28—Artificial amino acid sequence (NNJA_17)

[0220] FT SPPTEPR

[0221] SEQ ID NO: 29—Artificial amino acid sequence (NNJA_18)

[0222] MGNWTPHGT

[0223] SEQ ID NO: 30—Artificial amino acid sequence (NNJA_19)

[0224] MTSSRDAPA

[0225] SEQ ID NO: 31—Artificial amino acid sequence (NNJA_20)

[0226] MSRQ SVHTT

[0227] SEQ ID NO: 32—Artificial amino acid sequence (NNJA_21)

[0228] FTSQTKVAM

[0229] SEQ ID NO: 33—Artificial amino acid sequence (NNJA_22)

[0230] MSRPSSTLL

[0231] SEQ ID NO: 34—Artificial amino acid sequence (NNJA_23)

[0232] MSTPLDRTN

[0233] SEQ ID NO: 35—Artificial amino acid sequence (NNJA_24)

[0234] MQMAT STPA

[0235] SEQ ID NO: 36—Artificial amino acid sequence (NNJA_25)

[0236] MSKPTRLPV

[0237] SEQ ID NO: 37—Artificial amino acid sequence (NNJA_26)

[0238] LTTTRSLP S

[0239] SEQ ID NO: 38—Artificial amino acid sequence (NNJA_27)

[0240] MGSPPTYRP

[0241] SEQ ID NO: 39—Artificial amino acid sequence (NNJA_28)

[0242] MSLKSTPHP

[0243] SEQ ID NO: 40—Artificial amino acid sequence (NNJA_29)

[0244] MSTAPP SRT

[0245] SEQ ID NO: 41—Artificial amino acid sequence (NNJA_30)

[0246] MT SPNIAEP

[0247] SEQ ID NO: 42—Artificial amino acid sequence (NNJA_31)

[0248] ASKVPPSGP

[0249] SEQ ID NO: 43—Artificial amino acid sequence (NNJA_32)

[0250] AASTRPPQL

[0251] SEQ ID NO: 44—Artificial amino acid sequence (NNJA_33)

[0252] MSQRLSHHD

[0253] SEQ ID NO: 45—Artificial amino acid sequence (NNJA_34)

[0254] RLAKAPPVS

[0255] SEQ ID NO: 46—Artificial amino acid sequence (NNJA_35)

[0256] MSRTNTTVN

[0257] SEQ ID NO: 47—Artificial amino acid sequence (NNJA_36)

[0258] MSNPLSLPA

[0259] SEQ ID NO: 48—Artificial amino acid sequence (NNJA_37)

[0260] MSNTFHR SE

[0261]

[0262] SEQ ID NO: 50 - Nucleic acid sequence of engineered pIII comprising amino acid sequence (clone_G3) of 1X104

[0263]

[0264]

[0265] SEQ ID NO: 52 - Nucleic acid sequence of engineered pIII comprising amino acid sequence of 1X104 (clone_D4)

[0266]

[0267] SEQ ID NO: 53 - Nucleic acid sequence of engineered pIII comprising amino acid sequence of 1X104 (clone_F4)

[0268]

[0269] SEQ ID NO: 54 - Nucleic acid sequence of engineered pIII comprising amino acid sequence of 1X104 (clone_B4)

[0270]

[0271] SEQ ID NO: 55 - Nucleic acid sequence of engineered pIII comprising amino acid sequence (clone_A4) of 1X104

[0272]

[0273] SEQ ID NO: 56 - Nucleic acid sequence of engineered pIII comprising amino acid sequence of 1X104 (clone_F1)

[0274]

[0275] SEQ ID NO: 57-8+11 Nucleic acid sequence of vector

[0276]

[0277] SEQ ID NO: 58-H4 phage nucleic acid sequence of 8P+11P vector

[0278]

[0279] SEQ ID NO:59 - pill nucleic acid sequence of wild-type M13 bacteriophage

[0280]

[0281] SEQ ID NO:60—Amino acid sequence of wild-type M13 phage pillI amino acid sequenceAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVVVCTGDETQCYGTWVPIGLAIPENEGGGSEGGGSEGGGSEGGGTKPPEYGDTPIPGYTYINPLDGTYPPGTEQNPANPNPSLEESQPLNTFMFQNNRFRNRQGALTVYTGTVTQGTDPVKTYYQYTPVSKAMYDAYWNGKFRDCAF HSGFNEDPFVCEYQGQSSDLPQPPVNAGGGSGGGSGGGSEGGGSEGGGSEGGGSEGGGSGGGSSGDFDYEKMANANKGAMTENADENALQSDAKGKLDSVATDYGAA IDGFIGDVSGLANGNGATGDFAGSNSQMAQVGDGDNSPLMNNFRQYLPSLPQSVECRPFVFSAGKPYEFSIDCDKINLFRGVFAFLLYVATFMYVFSTFANILRNKES

[0282] SEQ ID NO: 61—wt pIII nucleic acid sequence of M138+11 phage vector

[0283]

[0284] SEQ ID NO: 62 (mature bacteriophage M13 surface protein P.III, encoded by recombinant and WT g.III genes (without signal peptide))

[0285] AETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVVVCTGDETQCYGTWVPIGLAIPENEGGGSEGGGSEGGGSEGGGTKPPEYGDTPIPGYTYINPLDGTYPPGTEQNPANPNPSLEESQPLNTFMFQNNRFRNRQGALTVYTGTVTQGTDPVKTYYQYTPVSSKAMYDAYWNGKFRDCAFHSGFNED LFVCEYQGQSSDLPQPPVNAGGGSGGGSGGGSEGGGSEGGGSEGGGSEGGGSGGGSGSGDFDYEKMANANKGAMTENADENALQSDAKGKLDSVATDYGAAIDGFIGDVSGLANGNGATGDFAGSNSQMAQVGDGDNSPLMNNFRQYLPSLPQSVECRPFVFGAGKPYEFSIDCDKINLFRGVFAFLLYVATFMYVF STFANILRNKES

[0286] SEQ ID NO: 63 (Mature, mutated bacteriophage M13 surface protein P.III (L8P+S11P amino acid substitutions) encoded by mutated wild-type g.III (without signal peptide)) AETVESCPAKPHTENSFTNVWKDDKTLDRYANYEGCLWNATGVVVCTGDETQCYGTWVPIGLAIPENEGGGSEGGGSEGGGSEGGGTKPPEYGDTPIPGYTYINPLDGTYPPGTEQNPANPNPSIEESQPLNTFMFQNNRFRNRQGALTVYTGTVTQGTDPVKTY YQYTPVSSKAMYDAYWNGKFRDCAFHSGFNEDLFVCEYQGQSSDLPQPPVNAGGGSGGGSGGGSEGGGSEGGGSEGGGSEGGGSGGGSSGDFDYEKMANANKGAMTENADENA LQSDAKGKLDSVATDYGAAIDGFIGDVSGLANGNGATGDFAGSNSQMAQVGDGDNSPLMNNFRQYLPSLPQSVECRPFVFGAGKPYEFSIDCDKINLFRGVFAFLLYVATFMYVF STFANILRNKES

[0287]

[0288] SEQ ID NO: 65 (Nucleotide sequence of mutated wild-type g.III gene (encoding L8P+S11P amino acid substitution) (without signal peptide coding sequence))

[0289]

[0290] SEQ ID NO: Amino acid sequence of wt pIII of phage vector 66 - M138 + 11 AETVESCPAKPHTENSFTNVWKDDKTLDRYANYEGCLWNATGVVVCTGDETQCYGTWVPIGLAIPENEGGGSEEGGGSEGGGTKPPEYGDTPIPGYTYINPLDGTYPPGTEQNPANPNPSLEESQPLNTFMFQNNRFRNRQGALTVYTGTVTQGTDPVKTYYQYTPVSSKAMYDAYWNGKFRDCAFHSGFNEDLFVCEYQGQSSDLPQPPVNAGGGSGGGSGGGSEGGGSEGGGSEGGGSEGGGSGGGSGSGDFDYEKMANANKGAMTENADENALQSDAKGKLDSVATDYGAAIDGFIGDVSGLANGNGATGDFAGSNSQMAQVGDGDNSPLMNNFRQYLPSLPQSVECRPFVFGAGKPYEFSIDCDKINLFRGVFAFLLYVATFMYVF STFANILRNKES

[0291]

[0292] SEQ ID NO: Amino acid sequence of pIII of phage vector 68-M138+11 AETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVVVCTGDETQCYGTWVPIGLAIPENEGGGSEGGGSEGGGSEGGGTKPPEYGDTPIPGYTYINPLDGTYPPGTEQNPANPNPSLEESQPLNTFMFQNNRFRNRQGALTVYTGTVTQGTDPVKTYYQYTPVSSKAMYDAYWNGKFRDCAFHSGFNEDPFVCEYQGQSSDLPQPPVNAGGGSGGGSGGGSEGGGSEGGGSEGGGSEGGGSGGGSGSGDFDYEKMANANKGAMTENADENALQSDAKGKLDSVATDYGAAIDGFIGDVSGLANGNGATGDFAGSNSQMAQVGDGDNSPLMNNFRQYLPSLPQSVECRPYVFGAGKPYEFSIDCDKINLFRGVFAFLLYVATFMYVFSTFANILRNKES

Claims

1. A modified bacteriophage pilli coat protein of the following formula (from amino terminus (N terminus) to carboxyl terminus (C terminus)): display peptide-N1-GS1-N2-GS2-CT, wherein the C terminus of the display peptide is fused to the N terminus of N1, and wherein within GS1 and GS2 of the pilli coat protein, there are a total of 1 to 4 exogenous peptidase recognition amino acid sequences.

2. The modified pill coat protein of claim 1, wherein the bacteriophage is a filamentous phage.

3. The modified pill coat protein of claim 1 or 2, wherein the filamentous bacteriophage is M13 bacteriophage.

4. The modified pill coat protein of any one of claims 1 to 3, wherein the M13 bacteriophage is otherwise encoded by a nucleic acid sequence as shown in SEQ ID NO: 1, 2 or 57. 5 . The modified pill coat protein according to claim 1 , wherein a total of 1 to 3 exogenous peptidase recognition amino acid sequences are present in GS1 and GS2 of the pill coat protein. 6 . The modified pill coat protein according to claim 1 , wherein a total of 2 exogenous peptidase recognition amino acid sequences exist in GS1 and GS2 of the pill coat protein.

7. The modified pill coat protein according to any one of claims 1 to 6, wherein an exogenous peptidase recognition amino acid sequence is present in GS1 and GS2 of the pill coat protein.

8. The modified pill coat protein according to any one of claims 1 to 6, wherein there is an exogenous peptidase recognition amino acid sequence inserted into the GS1 linker or the GS2 linker of the pill coat protein.

9. The modified pill coat protein according to any one of claims 1 to 8, wherein at least one exogenous peptidase recognition amino acid sequence is FLVIR (SEQ ID NO: 4).

10. The modified pill coat protein according to any one of claims 1 to 9, wherein an exogenous peptidase recognition amino acid sequence is inserted into the GS2 linker of the pill coat protein.

11. The modified pill coat protein according to any one of claims 1 to 9, wherein the exogenous peptidase recognition amino acid sequence is inserted into the GS1 linker of the pill coat protein.

12. The modified pill coat protein of any one of claims 1 to 11, wherein the displayed peptide is a cell penetrating peptide (CPP) or a putative CPP.

13. A bacteriophage comprising the modified pill coat protein of any one of claims 1 to 12.

14. A phage library comprising a plurality of phages according to claim 13.

15. The phage library of claim 14, wherein the modified pill coat protein comprises an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NOs: 49-56.

16. A method for preparing an engineered bacteriophage having a modified pill coat protein, comprising the steps of: (a) modifying the pill coat protein of a bacteriophage to contain a total of 1 to 4 exogenous peptidase recognition amino acid sequences in GS1 and GS2 of the pill coat protein, and (b) Obtaining an engineered phage having a modified pill coat protein of the following formula (from amino terminus (N terminus) to carboxyl terminus (C terminus)): display peptide-N1-GS1-N2-GS2-CT, wherein the C terminus of the display peptide is fused to the N terminus of N1.

17. The method of claim 16, wherein at least one foreign peptide recognition amino acid sequence is inserted into the glycine / serine (GS) 1 linker and the GS2 linker of the modified pill coat protein.

18. The method of claim 17, wherein at least one exogenous peptidase amino acid sequence is inserted into the GS1 linker of the modified pill coat protein.

19. The method of claim 18, wherein at least one exogenous peptidase amino acid sequence is inserted into the GS2 linker of the modified pill coat protein.

20. The method of claim 19, wherein the modified pill comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 49-56.

21. The method of claim 20, wherein the displayed peptide is a CPP or a putative CPP.

22. A method for screening clones that avoid lysosomal compartments from an engineered phage library, the method comprising the steps of: Providing an engineered phage library according to any one of claims 14-15; exposing the engineered phage library to a target cell population for a predetermined period of time to obtain internalized engineered phage; washing the target cell population to remove uninternalized engineered phage and obtain a washed target cell population; lysing the washed target cell population and obtaining recovered internalized engineered phage; as well as Recovered engineered phages were identified as clones that avoided the lysosomal compartment in the target cell population.

23. The method of claim 22, further comprising the steps of: Prior to the step of identifying the recovered engineered phage as clones that have avoided the lysosomal compartment in the target cell population, the recovered internalized engineered phage are amplified.

24. The method of claim 22 or 23, wherein the target cell population is a eukaryotic cell population.

25. The method of claim 24, wherein the eukaryotic cell population is a mammalian cell population.

26. The method of claim 25, wherein the mammalian cell population is selected from pancreatic beta cells, adipocytes, alveolar epithelial cells, fibroblasts, skeletal muscle cells, cardiomyocytes, CHO cells, 293 cells, CaCo2 cells or neurons, including but not limited to dorsal root ganglion (DRG) neurons and hypothalamic neurons.

27. A method for screening phages sensitive to lysosomal enzymes from an engineered phage or an engineered phage library, the method comprising the following steps: Providing an engineered phage library according to any one of claims 14-15; exposing the engineered phage library to a lysosomal enzyme for a predetermined period of time to obtain cleaved engineered phage and uncleaved engineered phage; and Identification of phages cleaved by lysosomal enzymes.

28. The method of claim 27, wherein the lysosomal enzyme is a cathepsin.

29. The method of claim 28, wherein the cathepsin is selected from the group consisting of cathepsin A, B, C, D, H, L, and S.

30. A method for screening putative cell penetrating peptides (CPPs), the method comprising the steps of: Providing an engineered phage library according to any one of claims 14-15; exposing the engineered phage library to a first target cell population for a predetermined period of time to obtain internalized engineered phage; washing the first target cell population to remove uninternalized engineered phage and obtain a washed target cell population; lysing the washed first target cell population and obtaining recovered internalized engineered phage; exposing the recovered internalized engineered phage to a second target cell population for a predetermined period of time to infect the second target cell population and obtain amplified recovered internalized engineered phage; and Amplified recovered engineered phage are identified for clones that avoid the lysosomal compartment in the first target cell population.

31. The method of claim 30, wherein the first target cell population is a eukaryotic cell population.

32. The method of claim 31, wherein the eukaryotic cell population is a mammalian cell population.

33. The method of claim 32, wherein the mammalian cell population is selected from pancreatic beta cells, adipocytes, alveolar epithelial cells, fibroblasts, skeletal muscle cells, cardiomyocytes, CHO cells, 293 cells, CaCo2 cells or neurons, including but not limited to dorsal root ganglion (DRG) neurons and hypothalamic neurons.

34. A CPP selected from the group consisting of SEQ ID NOs: 12-48.

35. A compound comprising: 1) a CPP identified by use of the method of any one of claims 22-33; and 2) a peptide, protein, LNP, PLV, mRNA, iRNA, siRNA, ASO, mAb fragment, or small molecule.